The same three PDFs are also retained in the COA, HPLC, and MS product tabs for quick access
Weight-related examples include exploring the potential for GLP-1s: Reduce the risk of cardiovascular events in adults with obesity and cardiovascular disease (CVD) Reduce complications from heart failure, sleep apnea, peripheral artery disease, and non-alcoholic steatohepatitis (NASH) in patients with obesity Researchers are also evaluating the effects of GLP-1s on diabetic retinopathy and even Alzheimers disease
Obesity and Diabetes Trends in America Current Obesity Prevalence and Geographic Distribution The United States faces an unprecedented obesity crisis, with 40.3% of adults classified as obese during 2021-2023 ^27
Univariate analysis identified pre-Tx Met, Orn, and post-Tx MetO, Orn, in addition to known markers AFP and FIB-4
Several studies have shown that tirzepatide reduces insulin resistance, improves glycemic control, and lowers inflammatory biomarkers, including C-reactive protein and IL-6 (46, 47)
